Malaysian pharmaceutical company Duopharma Biotech Berhad is a strategic partner that has secured the rights to our stem
cell therapy products in four Southeast Asian countries (Malaysia, Singapore, Brunei, and the Philippines).
We and the University of Utah Cell Sheet Tissue Engineering Center (CSTEC) are developing a treatment
anti-fibrosis with a cell sheet using our high-purity stem cells.
We are preparing to conduct clinical trials in Korea for Spinocerebellar Ataxia stem cell therapy
developed by Taiwanese stem cell company Steminent Biotherapeutics
Allele Biotechnology, an American stem cell company that started joint research with our company in 2019,
has a unique technology to produce induced pluripotent stem cells with mRNA technology.
We are jointly developing cell therapy for the treatment of diabetes using induced pluripotent stem cell-derived beta cells.
Vita Therapeutics, an American cell therapy company that we invested in 2021, is a venture company established based on
the technology developed at Johns Hopkins University in the United States.
We have signed a technology transfer contract for atopic dermatitis stem cell treatment with Handok,
and phase 3 clinical trials and product approval are scheduled to be carried out at Handok.